Cargando…

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium

BACKGROUND: Focal adhesion kinase (FAK) autophosphorylation seems to be a potential therapeutic target but little is known about the role and prognostic value of FAK and pFAK in epithelial ovarian cancer (EOC). Recently, we validated a gene signature classifying EOC patients into two subclasses and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aust, Stefanie, Auer, Katharina, Bachmayr-Heyda, Anna, Denkert, Carsten, Sehouli, Jalid, Braicu, Ioana, Mahner, Sven, Lambrechts, Sandrina, Vergote, Ignace, Grimm, Christoph, Horvat, Reinhard, Castillo-Tong, Dan Cacsire, Zeillinger, Robert, Pils, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998046/ https://www.ncbi.nlm.nih.gov/pubmed/24655477 http://dx.doi.org/10.1186/1476-4598-13-67

Ejemplares similares

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium
por: Obermayr, Eva, et al.
Publicado: (2017)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium
por: Pils, Dietmar, et al.
Publicado: (2013)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
por: Svoboda, Martin, et al.
Publicado: (2016)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer
por: Meshcheryakova, Anastasia, et al.
Publicado: (2019)

pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma
por: Thanapprapasr, Kamolrat, et al.
Publicado: (2017)

Correction: pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma
Publicado: (2017)

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome
por: Auer, Katharina, et al.
Publicado: (2015)

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?
por: Sukhbaatar, Nyamdelger, et al.
Publicado: (2017)

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study
por: Watrowski, Rafał, et al.
Publicado: (2022)

A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types
por: Pils, Dietmar, et al.
Publicado: (2020)

Correlation of circular RNA abundance with proliferation – exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2015)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer
por: Auer, Katharina, et al.
Publicado: (2016)

EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs
por: Reiner, Agnes T., et al.
Publicado: (2017)

Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2016)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2017)

Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2015)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2018)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
por: Ruscito, Ilary, et al.
Publicado: (2018)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
por: Noske, Aurelia, et al.
Publicado: (2011)

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group
por: Trillsch, Fabian, et al.
Publicado: (2021)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Ambivalent antihistamines.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_ge9kmnkp0tim8fpb774mr83tml